CareDx
CDNAMarket price data through November 13, 2026.
Performance
Nov 2021 – Nov 2026
Track record
How this pick has done since Benson first called it.
- Benson Return
- +10%
- How much this stock is up since Benson first picked it — measured from the price at the time of that first pick, not from today.
- First pick price
- ~$71
- Roughly what one share cost when Benson first picked this stock. This is the starting line for the Benson Return.
- Tracking since
- October 2026
- The month this stock first became a Benson pick.
- Tracking duration
- 0 months
- How long Benson has been tracking this pick.
About CareDx
CareDx makes blood tests that tell doctors early if a transplanted kidney, heart or lung is being rejected, without surgery to take a tissue sample. Think of it as a smoke alarm for a new organ. It also runs a pharmacy and patient support services, and since July it sells a blood test that tracks certain head and neck cancers after treatment.
The case for and against
Both sides of the story, in plain English.
- Testing Takes Off
Testing revenue jumped 65% to 119 million dollars last quarter, and the number of tests grew 51% to about 75,900, helped by the new NavDx cancer test. Even without catch-up payments for older tests, testing revenue grew about 58%. Total revenue rose 39% to 139 million dollars, even after the company sold its lab supplies business in June.
- Profits Pick Up
Cash profit before some accounting items doubled to 30 million dollars last quarter, and reported profit jumped to 19 million dollars from 2 million a year ago. The company raised its 2026 sales forecast to between 520 and 530 million dollars, and its full year cash profit forecast to 90 to 100 million dollars, up from 66 to 78 million. Raising the forecast again is a sign that demand is holding up.
- Priced For Perfection
The shares have rocketed more than fivefold in a year and jumped over 20% in a single day after the report. The company is now valued at about 4.6 billion dollars, roughly nine times the sales it expects this year. A lot of good news is already baked into the price, so any stumble could hit hard. The shares also tend to swing more than twice as much as the overall market.
- One-Time Boosts
About 15 million dollars of testing revenue last quarter was catch-up payments for older tests, up from 6 million a year ago. Cash coming in from operations was just 13 million dollars, well below the 30 million dollar cash profit figure, and cash on hand fell from about 374 million to 250 million dollars after paying 160 million dollars for cancer-testing firm Naveris, with up to 100 million more possible.
Other companies we track
How to read this page
This automated research summary uses Financial Modeling Prep market data through 2026-11-13. Model signals, scores, and risk labels can change and may be incomplete or wrong.
Want Benson to watch CDNA for you?
Get the app to follow every Benson pick live — and let Benson do the research for you.
